| Objective:To evaluate the clinical efficacy,pulmonary function and quality of life of patients with Chronic Obstructive Pulmonary Disease(COPD)before and after treatment by using different scales,focusing on the application of Mongolian and Western medicine in patients with COPD,and then to provide an effective reference for better improvement of the diagnosis and treatment of patients with COPD and improve their pulmonary function and quality of life.Method:Eighty patients with COPD who were diagnosed in the Affiliated Hospital of Inner Mongolia University for Nationalities and the Third Clinical Hospital from November 2018 to January 2020 were selected as the subjects of this study and divided into the observation group(n=40)and the control group(n=40)according to the method of random number table.There was no significant difference in the paired factors.Among them,the observation group was treated with ICS+LABA+LAMA combined with Qiwei grape powder,while the control group was treated with ICS+LABA+LAMA for a total of one month.Pulmonary function parameters,including forced expiratory volume in one second(FEV1),forced expiratory volume in one second(FEV1%),forced expiratory volume in one second(FEV1%),forced expiratory volume in one second(FEV1/FVC)and peak expiratory flow(PEF),were observed before treatment and after 1 month.6-minute walk test(6 MWT),modified dyspnea index(mMRC),stable patient self-assessment test(CAT)and quality of life were compared between the two groups before and after treatment for objective assessment.Establish a database,use SPSS 20.0 software package for statistical data processing,carry out t-test,analysis of variance and other statistical methods to analyze the results of the above relevant indicators and clinical significance.Results:(1)General data of patients in the two groupsA total of 80 patients with COPD were enrolled in this study.The patients were divided into observation group(n=40)and control group(n=40)according to random number table.The data of observation group included 26 males and 14 females,aged 50-62 years,mean age(58.12 ± 8.47)years,disease course 4-10 years,mean disease course(6.12±1.84)years,disease severity:28 cases of grade Ⅲ,12 cases of grade Ⅳ.The patients in control group included 21 males and 19 females,aged 52-65 years,mean age(59.40 ±6.82)years,disease course 4-10 years,mean disease course(5.85 ± 1.73)years,disease severity:26 cases of grade Ⅲ,14 cases of grade Ⅳ.After comparison,there was no statistically significant difference in age,gender,disease duration and other related paired factors between the two groups,with comparability(P>0.05).(2)Comparison of the clinical efficacy of treatment between the observation group and the control group included in the studyAfter comparison,the apparent efficiency of the observation group was 40.00%,the effective rate was 52.50%,the invalid rate was 7.50%,the total effective rate was 92.50%,the control group was 30.00%,the effective rate was 47.50%,and the ineffective Was 22.50%,the total effective rate was 77.50%,and there was a statistically significant difference in the total effective data between groups(P<0.05)(3)Comparison of pulmonary function before and after treatment between the two groupsBefore treatment,there was no statistically significant difference between the two groups of patients related to lung function indexes such as FEV1,FEV1%,FEV1/FVC,PEF(P>0.05).After treatment,FEV1,FEV1%,FEV1/FVC,PEF and other lung function-related indicators showed different degrees of improvement,and the improvement of the observation group was significantly better than that of the control group.The difference between the two groups before and after treatment and between the groups was statistically significant(P<0.05).However,there was no statistically significant difference in PEF before and after treatment and between groups(P>0.05).(4)Comparison of mMRC,CAT and 6 MWT related indicators before and after treatment between the two groupsAfter treatment,the improvement of mMRC,CAT and 6 MWT indicators after treatment in the observation group was superior to that before treatment.The mMRC and CAT indicators after treatment in the control group were also superior to those before treatment(P<0.05).However,the 6 MWT indicators after treatment in the control group were not significantly different from those before treatment(P>0.05).In addition,the mMRC,CAT and 6 MWT related indicators after treatment in the observation group were significantly superior to those after treatment in the control group,and the differences had statistical significance(P<0.05).(5)To observe the quality of life of patients in the control group before and after treatmentAfter follow-up,it was found that the respiratory symptom score,activity score,disease impact score and total score of the observation group were(69.59±9.11)points,(71.19 ± 8.92)points,(90.92 ± 9.23)points and(80.21± 7.34)points before treatment,(30.59±5.84)points,(44.54 ± 5.34)points,(62.28±5.29)points and(47.52±4.11)points after treatment,while the respiratory symptom score,activity score,disease impact score and total score of the control group were(68.91±9.03)points,(70.74±8.11)points,(90.44± 9.17)points and(80.30 ± 7.30)points before treatment,(48.29 ± 6.91)points,(55.29±6.69)points,(72.29±7.11)points and(55.23±5.82)points after treatment Among them,the quality of life score of the observation group was significantly lower than that of the control group and that before treatment,and the difference had statistical significance(P<0.05).Conclusion:The results of controlled trial found that the clinical efficacy of patients with COPD after treatment with Mongolian and Western medicine is more exact,which not only improves the pulmonary function of patients to a certain extent,but also further promotes the quality of life of patients with prognosis,providing a favorable reference for the clinical treatment of patients. |
PDF Full Text Request